Breaking Finance News

Baader Wertpapierhandelsbank disclosed Bayer (ETR:BAYN), boosting its stock price target to 81.00EUR earlier today

In a report issued Friday September 16 2016 Baader Wertpapierhandelsbank increased the target price of Bayer (ETR:BAYN) from 0EUR to 81EUR indicating a possible downside of -0.11%.

On 8/29/2016, Citigroup Corp. reported about Bayer(ETR:BAYN) upped the target price from 0.00EUR to 120.00EUR that suggested an upside of 0.24%.

Displaying a price of 91.44EUR, Bayer (ETR:BAYN) traded 0.00% even on the day. With the last stock price close up 1.82% relative to the 200-day moving average, compared to the S&P 500 Index which has decreased -0.01% over the same period. BAYN has registered a 50-day average of 0.04EUR and 200-day average of 0.03EUR. 0 shares of Bayer exchanged hands, down from ann avg. trading volume of 211

Recent Performance Graph:

Bayer (ETR:BAYN)

Bayer has a one-year low of 0.03EUR and a one-year high of 0.04EUR and has a total market value of 0.0 EUR.

Brief Synopsis On Bayer (ETR:BAYN)

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *